

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scheller, D.
Serial No.: **10/593,964**
Filed: 22 September 2006
Title: USE OF ROTIGOTINE FOR TREATING AND PREVENTING PARKINSON'S PLUS SYNDROME
Group Art Unit: 1614
Examiner: Javanmard, Sahar
Confirmation No.: 4037
Docket No.: **6102-000048/US/NP**
Client Ref.: P/SCHE/6/04

SUBMITTED ELECTRONICALLY VIA EFS-WEB

4 December 2009

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT B AND RESPONSE TO OFFICE ACTION DATED 5 AUGUST 2009
(INCLUDING PETITION FOR EXTENSION OF TIME UNDER 37 C.F.R. §1.136)
(INCLUDING SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97 (c))

This paper is responsive to the non-final Office Action dated 5 August 2009 in the above referenced application, in which a shortened statutory period of three months was set for reply. Applicant hereby makes petition for extension of time of one (1) month in which to submit the response. Authorization is provided herewith to charge the fee required under 37 C.F.R. §1.17(a)(1) to Deposit Account No. **08-0750**.

This paper also includes a supplemental information disclosure statement (IDS) under 37 C.F.R. §1.97(c). Authorization is hereby provided to charge the fee payable under 37 C.F.R. §1.17(p) to Deposit Account No. **08-0750**.

AMENDMENT UNDER 37 C.F.R. §1.111 (AMENDMENT B)

Amendment of the present application is requested as proposed herein.

Serial No. 10/593,964
6102-000048/US/NP
Response to Office Action dated 5 August 2009 and Supp. IDS
4 December 2009

Amendments IN THE CLAIMS begin on page 3 of this paper. By present amendment, no excess claim fee is believed due.

REMARKS on the present amendment begin on page 6 of this paper.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT begins on page 14 of this paper.